DOP2012000030A - Polipéptidos del factor ix modificados y usos de los mismos - Google Patents

Polipéptidos del factor ix modificados y usos de los mismos

Info

Publication number
DOP2012000030A
DOP2012000030A DO2012000030A DO2012000030A DOP2012000030A DO P2012000030 A DOP2012000030 A DO P2012000030A DO 2012000030 A DO2012000030 A DO 2012000030A DO 2012000030 A DO2012000030 A DO 2012000030A DO P2012000030 A DOP2012000030 A DO P2012000030A
Authority
DO
Dominican Republic
Prior art keywords
polipeptides
factor
same
modified factor
modified
Prior art date
Application number
DO2012000030A
Other languages
English (en)
Spanish (es)
Inventor
Chandra Patel
Xiaoqiao Jiang
Heiner Apeler
Jun Wang
Alan Brooks
Uwe Gritzan
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2012000030(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of DOP2012000030A publication Critical patent/DOP2012000030A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/644Coagulation factor IXa (3.4.21.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21022Coagulation factor IXa (3.4.21.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DO2012000030A 2009-07-31 2012-01-27 Polipéptidos del factor ix modificados y usos de los mismos DOP2012000030A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23055109P 2009-07-31 2009-07-31

Publications (1)

Publication Number Publication Date
DOP2012000030A true DOP2012000030A (es) 2012-02-29

Family

ID=43529743

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2012000030A DOP2012000030A (es) 2009-07-31 2012-01-27 Polipéptidos del factor ix modificados y usos de los mismos

Country Status (21)

Country Link
US (1) US20120164130A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2461821A4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2013500726A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20120060209A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN102573890A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2010278721A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112012002072A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2769258A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2012000238A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CR (1) CR20120052A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CU (3) CU20120018A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DO (1) DOP2012000030A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA201290069A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (1) ECSP12011637A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GT (1) GT201200023A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2012DN00908A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2012001346A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20121643A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG178119A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2011014890A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201200716B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2655639T3 (es) 2006-12-15 2018-02-21 Baxalta GmbH Conjugado de factor VIIa - ácido (poli)siálico que tiene una semivida in vivo prolongada
PT3581650T (pt) 2008-09-15 2023-03-08 Uniqure Biopharma B V Mutante de polipéptido de fator ix, as suas utilizações e um método para a sua produção
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
SG10201401194VA (en) 2009-07-27 2014-07-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
AU2010281453C1 (en) 2009-07-27 2019-08-15 Takeda Pharmaceutical Company Limited Blood coagulation protein conjugates
SG178051A1 (en) 2009-07-27 2012-03-29 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
SG187171A1 (en) * 2010-07-30 2013-02-28 Baxter Int Nucleophilic catalysts for oxime linkage
HUE049352T2 (hu) 2010-12-22 2020-09-28 Baxalta GmbH Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására
PT2794665T (pt) * 2011-12-19 2018-01-24 Dilafor Ab Glicosaminoglicanos não anticoagulativos que compreendem unidade repetitiva de dissacáridos e sua utilização médica
WO2014081831A1 (en) * 2012-11-20 2014-05-30 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor ix proteins
CA2901928C (en) * 2013-03-13 2017-10-10 Eli Lilly And Company Modified canine leptin polypeptides
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
TWI741992B (zh) 2015-08-03 2021-10-11 美商百歐維拉提夫治療公司 因子ix融合蛋白以及其製備及使用方法
EP3490586B1 (en) * 2016-07-27 2025-03-26 The Children's Hospital of Philadelphia Compositions and methods for modulating factor ix function
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
AU2019360270B2 (en) 2018-10-18 2025-08-07 Intellia Therapeutics, Inc. Compositions and methods for expressing factor IX.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002086091A2 (en) * 2001-04-25 2002-10-31 The Regents Of The University Of California Method to treat hemophilia by hepatic gene transfer of factor viii/ix with vesicle vector
NZ546733A (en) * 2003-12-03 2009-07-31 Novo Nordisk As Glycopegylated factor IX
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
TW200804416A (en) * 2006-06-19 2008-01-16 Nautilus Technology Llc Modified coagulation factor IX polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
WO2011014890A1 (en) 2011-02-03
GT201200023A (es) 2014-01-27
IN2012DN00908A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-04-03
SG178119A1 (en) 2012-03-29
CU20130058A7 (es) 2013-06-28
JP2013500726A (ja) 2013-01-10
BR112012002072A2 (pt) 2016-11-08
EA201290069A1 (ru) 2012-07-30
CR20120052A (es) 2012-06-04
ZA201200716B (en) 2013-07-31
ECSP12011637A (es) 2012-02-29
AU2010278721A1 (en) 2012-02-16
MX2012001346A (es) 2012-02-17
CU20120018A7 (es) 2012-06-21
EP2461821A1 (en) 2012-06-13
PE20121643A1 (es) 2012-11-25
CN102573890A (zh) 2012-07-11
EP2461821A4 (en) 2013-07-03
CL2012000238A1 (es) 2012-10-05
US20120164130A1 (en) 2012-06-28
CA2769258A1 (en) 2011-02-03
CU20130057A7 (es) 2013-06-28
KR20120060209A (ko) 2012-06-11

Similar Documents

Publication Publication Date Title
DOP2012000030A (es) Polipéptidos del factor ix modificados y usos de los mismos
SV2010003704A (es) Polipeptidos modificados del factor ix y usos de los mismos
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
CR20140512A (es) Dispositivos y metodos para la fabricación de aditivos de componentes de implante
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
HN2010000084A (es) Derivados de sulfonamida
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
CL2015002941A1 (es) Usos terapéuticos de empaglifozina
MX2015011445A (es) Compuestos y usos de estos para la modulacion de la hemoglobina.
CO6501131A2 (es) Antagonistas de espiro-oxindol de mdm2
NI201000044A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
PE20150631A1 (es) Formas cristalinas de un modulador del receptor androgenico
CR20140476A (es) Agentes para tratar transtornos que implican la modulación de receptores de rianodina
CR20150067A (es) Pirazoles sustituidos como bloqueadores del canal de calcio tipo n
ECSP109923A (es) Bromhidrato de bupropion y aplicaciones terapéuticas
MX2017014245A (es) Composiciones que comprenden celulas germinales mesenquimales y usos de las mismas.
BR112013005855A2 (pt) heteroarilas fundidas e seus usos
UY34773A (es) Ácidos indanoiloxidihidrobenzofuranilacéticos como moduladores de la actividad de gpr40, composiciones que los contienen y sus usos
CR11631A (es) Paramyxovirus eficaz como antitumoral
CR20150070A (es) Pirrolopirazoles como bloqueadores del canal de calcio tipo n
UY33833A (es) Proteína de fusión Robo1-Fc para su uso en el tratamiento del hepatocarcinoma
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
BR112014031706A8 (pt) Composições farmacêuticas orais, e composição farmacêutica oral compreendendo itraconazol
MX372807B (es) Copolimeros de bloque para proteccion del esmalte dental.
MX2016005227A (es) Polipéptidos de acción prolongada y métodos para su producción y administración.